Podcasts about standard of care

Escaping "Half Truths" of the Medical Industry with Dr. Joseph JackoTIMESTAMPS:00:00 Intro Snip00:57 Introduce Dr. Joseph Jacko author of Bamboozled, Duped, and Hoodwinked02:10 How does Dr. Jacko still have a license considering he is exposing things in medicine05:20 Dr. Haley reads some surprising content from Dr. Jacko's book regarding the 100% risk reduction of a vaccine07:57 Why did medical doctors push the Covid vaccine considering the actual risk reduction?09:39 How smart are medical doctors?11:00 What is the purpose of a medicine? Do they cure anything?14:00 What should the goal of medicine be?14:58 What is the reason most doctors don't give lifestyle advice?15:35 Why don't we have time to spend with our patients?17:32 Dr. Haley explains why healthcare has gotten more expensive and explains the concept he sent to President Obama.21:07 Why doesn't Dr. Jacko take health insurance anymore?22:30 Dr. Haley explains how his study of drug advertising on TV demonstrated how people are exposed to 3 to 5 thousand drug advertisements per year on TV alone.24:10 Who is controlling the people's beliefs that drugs are the answer?25:20 Where does the FDA get their funds from?26:03 Who else are pharmaceutical companies funding and likely influencing?29:20 What medicine does Dr. Jacko take?30:35 What does the science say about aloe vera and cancer?32:00 What does Dr. Joseph Jacko do in his practice?34:39 What is Mainstream Medicine? 35:27 What medications can actually contribute to longevity?36:30 Does insurance pay for actual "Health Care"?37:37 What criteria do you use when choosing which vaccines to get?41:05 How does "Standard Of Care" affect what doctors do?42:26 Why might some doctors not allow patients return when they refuse vaccines?43:28 What power words were spoken to you?45:20 What is the "Top 40 Not So Wacko Jacko Rules Of Medicine"

Liz is joined on the podcast by Becky Lai, Chief Strategist and VP of Marketing, to talk about the true North Star of commercialization: standard of care. Their discussion reframes success as more than building a product—it's about building a market where the product is trusted, adopted, and indispensable. Together, they explore how purposeful training, meaningful KOL engagement, and a clear strategic vision accelerate adoption and move technologies from launch to lasting impact.In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:Rebecca Lai is the Chief Strategist and Marketing Executive at Rebecca Lai Consulting. She is a strategy and commercial executive with over 20 years of experience in medical and health technology companies, ranging from venture-backed startups to Fortune 200 corporations. As a dynamic strategic operator specializing in go-to-market, commercialization, and innovative business strategies, she has consistently driven double-digit growth and scaled new businesses with global impact. With a strong background in devices, diagnostics, and the digital transformation of healthcare, Rebecca has a proven track record of pioneering disruptive solutions across the continuum of care. Most recently, she was VP of Corporate Development and Strategy at iRhythm Technologies (NASDAQ:IRTC), a digital healthcare provider of cardiac monitoring services. She began her career at Medtronic (NYSE:MDT), where she held progressive global leadership roles in sales and marketing. Rebecca is recognized for her ability to navigate complexity and her data-driven, customer-centric approach to creating value and delivering cutting-edge products and services to patients worldwide. She holds a BSE and MSE in Bioengineering from the University of Pennsylvania and serves on the advisory board for Diversity by Doing Healthtech.Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe! Connect with us on LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Rebecca Lai⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠About Cumby Consulting:Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

Episode 063 | Today I'm bringing you an episode of The DermBiz Show in which I had the pleasure and opportunity of sharing some of my story and private practice journey.Show notes and audio content for this episode are courtesy of The DermBiz Show with Tony Jackson and Dr. Mercy Odueyungbo-Jackson, both of whom I can't wait to feature on this show! If you like what you hear, please watch and follow their show. You won't regret it. You can check out the full video here: https://youtu.be/qaRvkHp6z8o?si=LaMrEXA_Y9mqnoeBRaising the Standard of Care with Dr. Stephen LewellisDo you feel constrained in a corporate environment? Do you believe there is a better way to treat patients than the assembly-line model? Then this episode is for YOU.In this episode, Dr. Stephen Lewellis shares his journey from a corporate job to building his own private practice. He explains why "the standard of care is table stakes" and how he is raising the bar by focusing on his Four Core Pillars. Dr. Lewellis shows you how to humanize the patient experience, where patients are so delighted they actually want to pay for it.He offers a unique perspective on starting a practice, reminding us that building a business is "not med school hard" and that success comes down to having a sustained "WHY" to drive you forward.

Is Your Chiropractic Care Plan a Sales Pitch or a Health Strategy? Understanding the Difference | The Prime Podcast Have you ever left a doctor's office with a recommended care plan and felt a wave of skepticism? It's a common experience, especially in chiropractic, where the purpose behind a structured plan is one of the most misunderstood aspects of care. Patients often turn to social media forums, asking friends, "Does this seem right?" creating a massive gray area filled with confusion and misinformation. In Episode 343 of The Prime Podcast, Dr. Skip and Dr. Julie Wies pull back the curtain on this "taboo" topic. They explore why the concept of a care plan is so divisive and why clear communication between a doctor and a patient is the most critical factor for a successful health outcome. This episode is an essential guide for any patient who wants to feel empowered and confident in their healthcare decisions. The doctors break down the two fundamental philosophies of care you'll encounter: Symptomatic Care: The reactive, "quick fix" approach. This is for when you just want immediate pain relief for a headache or back pain and have no long-term goals. Vitalistic Care: The proactive, wellness-focused approach. This is for patients who want to address the root cause of their issues, prevent them from recurring, and achieve a higher standard of overall health. Using a brilliant "fruit salad vs. veggie salad" analogy, Dr. Skip and Dr. Julie illustrate what happens when a patient's expectations don't align with a doctor's standard of care. They discuss why a chiropractor who is truly invested in your long-term wellness will always recommend a plan, and why "just come in when it hurts" can lead to a cycle of recurring problems and the false belief that "chiropractic didn't work." Furthermore, they tackle the thorny issue of insurance, explaining why the best chiropractors are often out-of-network and why that should be seen as a green flag indicating a commitment to wellness over "sick care." KEY TAKEAWAYS Communication is Key: A successful healthcare experience depends on the patient and doctor being on the same page with their goals and expectations before care begins. Vitalistic vs. Symptomatic: Understand which philosophy your chiropractor follows. Are they focused on proactive wellness and fixing the root cause (vitalistic), or just reactive pain relief (symptomatic)? A Care Plan is a Standard of Care: A structured care plan is not a sales pitch; it is a doctor's professional recommendation based on your history, exam, and health goals to achieve lasting results. Don't Ask the Internet, Ask Your Doctor: If you have questions about your care plan, the most qualified person to answer them is the doctor who created it based on your specific case. Insurance Doesn't Dictate Health: The best healthcare providers often operate outside of insurance networks because they refuse to let a third party dictate a standard of care that is focused on sickness, not wellness.

Dr. Mark Boldt has been a successful Prosthodontist for many decades, with a fantastic local reputation and known for having a high standard of care. He shares lessons learned over his career, thoughts on analog/digital workflows, his trusted dental lab tips and so much more. Ladies & Gentlemen, you're listening to "Confessions From A Dental Lab" and we're happy you're here. Subscribe today and tell a friend so we can all get 1% better :)Connect with Dr. Boldt on instagram at @markaboldtdds and email him at m-boldt@sbcglobal.netFollow KJ & NuArt on Instagram at @lifeatnuartdental, you can also reach us via email: kj@nuartdental.comLearn more about the lab and request information via our website: https://nuartdental.com/contactAsk us about our scanner program!

Today, the legal technology sector is experiencing an unprecedented surge of capital and innovation. We are witnessing massive investments, such as Nexl's successful $35 million Series B funding round and over $250 million secured by plaintiff-focused AI platforms Eve and EvenUp to level the playing field for the plaintiffs' bar. This funding fuels the development of AI-driven growth platforms and potent solutions like Westlaw Advantage for unparalleled research efficiency and the emergence of hybrid AI law firms like Crosby. AI adoption is accelerating, dramatically improving efficiency, with individual users reporting substantial weekly time savings by automating tasks that range from legal research and contract drafting to internal firm operations and marketing content creation. However, this rapid technological shift is accompanied by significant professional and regulatory challenges. Law tech management platform Nexl nabs $35 million Series B2025-10-08 | Startup DailySome police departments are using AI to write reports2025-10-08 | Minnesota Public RadioTransform the Legal Function by Embracing Legal Data Intelligence IDC Sep 30, 2025 This IDC Perspective explores how legal data intelligence (LDI) is transforming legal functions by enabling legal teams to manage, analyze, and leverage vast volumes of dig2025-10-08 | MarketResearch.comThe ROI and future of AI in legal2025-10-08 | IManage.comSquire Patton Boggs Bolsters its Customs Tariffs and Trade Team with Senior Hire in Los Angeles2025-10-08 | Squire Patton BoggsClients Name the 32 Law Firms Best at Gen AI Litigation2025-10-08 | BTI ConsultingMake 2026 The Year You Start Your Law Firm2025-10-08 | My ShingleThe new public defender: Some are turning to ChatGPT to offer legal advice and win small claims cases2025-10-08 | AOL.com2025 LDO Index: Legal departments want better service enhancement, but success metrics don't always reflect priorities - Thomson Reuters Institute2025-10-08 | Thomson ReutersWith ‘Under Review,' Stanford Law Expands Its Podcast Lineup to Examine the Future of Law and Business2025-10-08 | Stanford Law SchoolNexl Bags $23m, Will Invest In Hires + Acquisitions2025-10-08 | Artificial LawyerHybrid AI Law Firm, Crosby, Raises $20m – Cooley Invests2025-10-08 | Artificial LawyerMeet Westlaw Advantage: The next generation AI legal research solution2025-10-08 | Legal.ThomsonReuters.comUS law school takes Genie AI to coach new generation of students2025-10-08 | Business Weekly UK3 Ways Lawyers Are Finding New Efficiencies With AI2025-10-08 | Above The LawHealthcare Law Careers Surge in 2025 — A Strategic Opportunity for Legal Professionals2025-10-08 | JDJournalAI Investments Surge as Legal Tech Startups Target Plaintiffs' Firms2025-10-08 | JDJournalEve Launches AI Intake Platform with Voice Agent for Plaintiffs' Firms2025-10-08 | LawSitesElevate Your Law Firm's Content Marketing Workflows: AI Tools Worth Exploring2025-10-08 | JD SupraClio founder talks $1B acquisition of vLex and upcoming Clio Cloud Conference2025-10-08 | ABA JournalAvoiding risk: AI's double-edged role in e-discovery2025-10-08 | ReutersLawyer AI Competence: Training Is Becoming Mandatory — But Lawyers Still Get Burned2025-10-08 | Articles, Tips and Tech for Law Firms and LawyersLaw Companies and Their Role in the Legal Market2025-10-08 | Elevate ServicesThese people ditched lawyers for ChatGPT in court2025-10-08 | NBC Bay AreaLucio Raises $5M in Funding2025-10-08 | FinSMEsLegal Innovators UK – Speaker Highlight: A&O Shearman's Helen Lightfoot2025-10-08 | Artificial LawyerState AI laws = economic, legal & security risks2025-10-08 | New York Daily NewsIntake Is Broken: Why Law Firms Can't Afford to Ignore AI2025-10-08 | Artificial LawyerItaly enacts Law No. 132/2025 on Artificial Intelligence2025-10-08 | Inside Tech Law

Ever wondered if X-rays are really necessary before a chiropractic adjustment? Or have you been told they're an optional, skippable step? In this vital episode of The Prime Podcast, Dr. Skip and Dr. Julie Wies tackle the growing misconception around spinal imaging and explain why skipping this step could put your health at risk. Many people seek chiropractic care for back pain, neck pain, or general wellness, but not all understand the importance of a proper diagnosis. An adjustment without a clear picture of your spinal health is just guesswork. Drs. Skip and Julie reveal what a trained chiropractor can see on an X-ray—from hidden fractures and dangerous pathologies to congenital abnormalities that could make a standard adjustment harmful. Discover why the X-ray and the chiropractic profession were born in the very same year and how this foundational tool is a non-negotiable "standard of care" for ensuring patient safety, achieving better results, and truly understanding the root cause of your health concerns. Don't let a practitioner gamble with your spine. Learn how to advocate for the highest standard of care. In this episode, you will learn: Why spinal X-rays are a foundational standard of care in chiropractic, not an upsell. The difference between "guessing" and "knowing" when it comes to your chiropractic adjustment. Real-life examples of serious conditions (cancer, aneurysms, hidden fractures) that were discovered through routine spinal imaging. A compelling case study of how an X-ray solved the mystery of a teenager's chronic migraines. The truth about radiation exposure from X-rays versus everyday activities like flying. What to do if your chiropractor has never taken an X-ray and how to find a practitioner who prioritizes your safety. Disclaimer: The content in this podcast is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

On this episode of IPA's What, Why & How podcast, IPA CEO Matt Pitlick welcomes Anne Schlepphorst, Bureau Chief of Monitoring and Executive Director of the Iowa Board of Pharmacy, for an update from the Board, covering standard of care, immunizations, and more. Anne Schlepphorst serves as the Executive Director of the Iowa Board of Pharmacy, Interim Executive Director of the Iowa Board of Nursing, and Monitoring Bureau Chief. Anne has worked with the boards for the past seven years, most recently serving as the Chief Investigator for the Iowa Boards of Pharmacy and Medicine. When not working, Anne and her husband spend most of their time at the baseball field, hockey rink, wrestling mat, or football field watching their two teenage boys. Connect with us on LinkedIn: Anne Schlepphorst Matthew Pitlick Iowa Pharmacy Association

At the intersection of medical innovation and compassionate, community-centered care, Driscoll Children's Hospital has emerged as a national leader in pediatric heart care and health equity. In this episode of Healthcare Insider, Dr. Stephen M. Langley, medical director and chief of pediatric cardiac surgery at Driscoll Children's Hospital, shares powerful insights into how the hospital is elevating care for complex and underserved pediatric populations across south Texas. From groundbreaking outcomes in congenital heart surgeries to culturally informed, family-centered care models, Dr. Langley outlines how Driscoll is redefining “best care” for children and what other healthcare leaders can learn from their approach.

AI-Driven CMR: Where Gold Standard Becomes Standard of Care

Hey Girl! You know those moments that just make life feel so full circle? Well, that's what this episode felt like when I was interviewing my special guest for the show this week! Almost 8 yrs ago, I was just like you, searching instagram and social media for “Pelvic floor Exercises”, “Pelvic Floor Physical Therapy”, “Pregnancy Safe Exercises”,  “Prenatal Pelvic Floor” and more! Coming Fresh out of Grad school, pregnant with my second baby and now aware that Pelvic Floor PT exists and that guess what… I didn't need to pee my pants the last 6 years?! So I was motivated to keep my leaking from getting worse during the pregnancy and starting diving more into Pelvic Floor Health. At the time, I knew the “What” and some of the “Why” leaking and other pelvic issues occurred and that they were not normal, but I had yet to learn the “How” to fix it.     So after searching for reliable sources on social media (yes they exist but you have to do your research), I found the one and only Vaginal Whisperer, Dr. Sara Reardon. Wearing a Vulva costume and talking about taboo topics like poop and sex, she caught my attention immediately.  I started doing some of the exercises she talked about on her page and started to really see a difference and ultimately healed all of my incontinence! She was and is, a trailblazer for Pelvic health and Women's Health in general as she continues to educate, empower and support women all over the world while breaking down cultural barriers. With that being said, I am so thrilled to have Dr. Sara Reardon on the show this week to dive more into her story and how she continues to elevate the standard of care for women in the US and inspire clinicians (like me) to do the same!    Dr. Sara Reardon is a board-certified pelvic floor physical therapist with over 18 years of experience helping individuals prevent and overcome pelvic floor issues including, urinary leakage, painful sex, prolapse and discomfort during pregnancy, postpartum and menopause. Sara has been featured in Time, Yahoo, Harper's Bazaar, Romper, InStyle, Today, and numerous other podcasts, publications, and professional conferences about her advocacy and educational work as a pelvic floor therapist. She is also a TED presenter on Rethinking Postpartum Care. Sara is the Founder of The V-Hive, an online, on-demand pelvic floor fitness platform for pregnancy, postpartum, menopause, painful sex and pelvic floor strengthening. Sara lives in New Orleans with her husband and two sons. FLOORED: A Complete Guide to Women's Pelvic Floor Health at Every Age and Stage is her first book.   To connect with Sara or order her book Floored, see links at bottom of show notes.   If you want more support from me, reach out for 1:1 or group coaching, join my FREE and Private support group below and DOWNLOAD my new APP Pelvic Floor, Core & More that has my on demand 12 wk program, tracking features, pelvic floor 101 masterclass and more!    RESTORE is my first 12 wk online signature program hosted inside my new platform that will be an APP soon Pelvic Floor, Core & More! Inside that program I walk you through the basics of healing, restoring your breathing, posture, core function and overall strength and return to impact and intensity.  All with the guidance of me, a Pelvic Floor PT, in your pocket making sure that you are getting individualized support and feedback through the program during our weekly group coaching calls! This option is great for those that can't afford a one-on-one session for $200-$240, those that don't have access to a pelvic floor PT in person or those that want to have a structured organized program with support as they are phasing out of acute therapy treatments and working more independently.    

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Join us for an engaging discussion with Chad Clary where we explore how architectural projects differ from movies and video games in terms of crediting contributors. We talk about whether the industry needs a better system for recognizing all those involved in building projects. The conversation also covers the critical importance of specificity in architectural documentation, examining how evolving professional roles affect design intent preservation while meeting contractor expectations.Episode Links:The Barnes Foundation by TWBTA-----Have a question for the hosts? Ask it at AskArchispeak.comThank you for listening to Archispeak. For more episodes please visit https://archispeakpodcast.com.Support Archispeak by making a donation.

Learn how your treatment plan is decided and terms you may seeWe continue our series to help you understand cancer and its treatment. This week we focus on surgery, the oldest form of cancer treatment. Learn about surgery timing, types of cancer surgery, and how NCCN evidence-based guidelines provide a standard treatment path no matter where you are.In this Episode:02:58 - Wisconsin-Cheese, UFOs, and Booyah Stew04:52 - Anna Quindlen: Get a Life Where You Are Generous"08:06 - Medical Specialists Involved in Cancer Care08:52 - Treatment Decisions, Tumor Board and NCCN Guidelines12:03 - Adjuvant and Neoadjuvant Therapy13:13 - Surgery Timing, Reasons and Types18:00 - Discussion - NCCN and Role of Research24:34 - Reeves Keyworth:“On Loved Ones Telling the Dying to ‘Let Go”23:54 - OutroSurgery, radiation therapy, and chemotherapy alone or in combination are the most-common methods used to treat cancer. Specific treatment varies depending on the kind of cancer, the extent of the disease, its rate of progression, and the condition of the person. Surgery alone may not result in a cure and often chemotherapy and/or radiation are needed after surgery. Learn all about surgery and the guidelines your doctor will be following for your treatment.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MFK865. CME/AAPA credit will be available until March 10, 2026.Leveling the Standard of Care in Hemophilia A: Insights & Strategies for Developing Effective, Personalized Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

Judy and Dennis (TheVascular Guy) discuss the importance of patient-centered care, the challenges of managing patients with sensitive skin sensitivities, and the need for alternative solutions like Covalon's dressings. They also explore the potential trend of increased skin sensitivity, the use of chlorhexidine and silicone-based dressings for patient care, and the importance of thorough patient assessment and providing multiple treatment options. The duo conclud by discussing the challenges of implementing cultural and administrative changes in healthcare systems, the importance of patch testing with products, and the need for improved practices in managing catheters.Thank you to Covalon for sponsoring this Podcast! www.covalon.comSupport the show

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University. Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors. Key topics covered in this episode: •⁠  ⁠The significance of recurrence scores in dictating adjuvant chemotherapy •⁠  ⁠The ongoing OFSET trial and its potential impact on treatment decisions •⁠  ⁠Insights into the use of genomic assays like MammaPrint and RS-Clin •⁠  ⁠The evolving landscape of treatment options for locally advanced and metastatic breast cancer •⁠  ⁠The latest on PARP inhibitors, T-DXd, and other novel therapies Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights! YouTube: https://youtu.be/_icBN3J3Bc0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #HR+ #breastcancer   #HormoneReceptorPositiveCancer #oncbrothers  #Podcast

This podcast was edited on a plane ride to Japan, and the intro was recorded in a bathroom while my kids slept off the jet lag. It's still good. I recently went down with Ben Greenzweig, the Executive Director of the non-profit Living Water Brain Treatment Center in Myrtle Beach, South Carolina. We are—right now—providing TMS treatment and, soon to be more, in a local community in Ben's beloved home of Horry County. There are 400,000 residents and less than 30 psychiatric inpatient beds in the county. There are not enough services to meet the needs he saw in his community—so he started Living Water to help. I'll remind readers that not only did he write an article about it, but he is also running a non-profit. Thus, consider donating.The audio from today's podcast was recorded mainly on my phone, which I had in my pocket as I gave the talk. Please share it with friends. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe

Dr Evelyn Ainsley McWilliams joins Ethics Talk to discuss her article, coauthored with Dr Lisa Bayer: “How Should Intensity and Duration of Pain Inform Standard of Care for Pain Management in Non-Labor and Delivery OB/GYN Procedures?”  Recorded December 3, 2024.  Read the full article for free at JournalOfEthics.org

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

This episode is a continuation of last week. It focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

This episode focuses on both the positive and negative medical experiences of people who have gone through infertility and loss. People wrote in and sent clips sharing about either a medical provider that was extremely helpful and supportive or one that was not supportive and needs improvement. Listen as they share their experiences and show there is no true standard of care when it comes to infertility or pregnancy and infant loss.

Send us a textThe Modern Urologist Podcast has launched a new miniseries, Precision Oncology and Prostate Cancer: The New Standard of Care, hosted by Dr. Paul Sieber and Ashleigh Renitsky, Oncology PA. This series will focus on the evolving role of genetic testing in prostate cancer care and its impact on personalized patient treatment plans.Episode #1 - Genetic testing basicsThe first installment will provide an overview of genetic testing, highlighting the difference between germline and somatic testing, and their implications for personalized treatment. This episode emphasizes the importance of integrating streamlined testing protocols into clinical practice, understanding test results to tailor therapies for patients, and leveraging genetic counselors. 

What is the standard of care? It's not a single document like the Declaration of Independence, so what is it and who decides what it is? In this episode Andrew talks through a few resources to help you find, establish, and implement the dental standard of care in your offices. He also gives a strong warning the the RDH profession... Resources: Https://www.perio.org Https://aap.org https://aacariology.org/about/

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

In Part II of this series on the standard of care, Dan continues his discussion with Colleen Palmer and Lou Gale by reviewing specific examples of where contract language can elevate the standard of care – and advice on how to negotiate this language out of a design professional's agreement to ensure a balanced – and insurable agreement.  We also discuss how the standard of care is evolving and what design firms should be prepared for to mitigate their risk.  

About Michael J. Lipson OD FAAO FSLSDr. Michael Lipson is recently retired from his position as an optometrist/associateprofessor at University of Michigan. His clinical practice involves specialty contact lenses:OrthoK, keratoconus, post-corneal transplant, post-refractive surgery and severe dry eye patients. He has published peer-reviewed clinical research studies on OrthoK, vision-related quality of life, myopia management and new lens designs. He lectures nationally and internationally at live and online venues on those same topics. Dr. Lipson developed a validated questionnaire to assess vision-related quality of life for all types of vision correction, including OrthoK. He has authored chapters in textbooks on OrthoK, scleral lenses and general contact lens topics. Dr. Lipson is the author of the book “Contemporary OrthoKeratology”. He is an independent consultant to the specialtycontact lens industry relative to OrthoK education and myopia management. He is on the GPLI Advisory Board, served as Vice-President of the Scleral Lens Education Society and served on the Scleral Lens Education Society Board for many years.https://journals.lww.com/optvissci/citation/2024/07000/letter_to_the_editor__myopia_management_is_now.2.aspxhttps://pubmed.ncbi.nlm.nih.gov/38546754/

In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.

The WHO recently stated that fluoride is, in fact, unsafe. After 60 years of being labeled a conspiracy theory, with experts reassuring the public about its safety, people should be concerned about taking the “experts” for their word. We should be doing our own research.   Pfizer's admission that they did not test certain aspects of their COVID-19 vaccine before marketing it as "safe" and "effective" raises serious questions. Can we keep on blindly trusting "expert" advice? In this episode, Brian Moody and Hans Toohey discuss why you need to become your own expert. They delve into what you must look out for before making decisions that greatly impact your or your family's lives. Tune in to learn about what Brian and Hans do to make more informed choices about their health and lives. Be Skeptical of What the “Experts” Say: Question everything. Just because an “expert” says something, doesn't mean it's infallible. If it concerns your body or impacts your life, take the initiative to do your own research instead of blindly trusting someone simply because they hold a PhD. Throughout history, there has been "common knowledge" that experts endorsed which later proved to be incorrect. Historical Narratives Should Be Re-examined: Don't hesitate to research and consider alternative viewpoints that challenge commonly accepted historical knowledge. Understanding that history is often presented with biases, and exploring different perspectives can give you a more comprehensive and accurate understanding of past events. Corporations Don't Want You To Get Better: Pharmaceutical companies prioritize profits over the well-being of individuals. Their decisions on product development, marketing, and distribution are driven more by financial gain than by public health benefits. Critically assess medical products and treatments, weighing their pros and cons before proceeding. Trust Yourself, Not Just Experts: Take personal responsibility and trust your own judgment. Whether it's about family health, financial decisions, or general well-being, strive to become the expert in your own life. Gather information, question the norms, and make informed decisions for the benefit of your family. Got Questions? Reach out to us at info@remnantfinance.com ⁠Visit https://remnantfinance.com for more information FOLLOW REMNANT FINANCE Youtube: @RemnantFinance (https://www.youtube.com/@RemnantFinance) Facebook: @remnantfinance (https://www.facebook.com/profile?id=61560694316588) Twitter: @remnantfinance (https://x.com/remnantfinance) TikTok: @RemnantFinance Don't forget to hit LIKE and SUBSCRIBE 

I'm sharing my latest medical adventure where the standard of care medical system tried to steer me into a hysterectomy. Why? Because a biopsy indicated complex atypical hyperplasia, and despite a CT scan showing no cancer, the recommendation was a full hysterectomy. But let me tell you, I wasn't about to jump into a life-altering surgery without peeling back every layer. And let me tell you, navigating this medical maze was a shocker. I dove into all the options, from hormone therapy to biopsies every three months, determined to advocate for my health. Through my story and insights from listeners who shared LIVE their own health hurdles, I unpack the importance of being informed and proactive. So, if you've ever felt lost in the medical system, this episode is your guide to standing firm and making empowered, educated decisions about your health. Trust me, you don't want to miss this! Shop ALL of Dr. Amie's Fixxr® Supplements: betterlifedoctor.com LET'S GET YOUR LIFE BACK...Connect with Dr. Amie Hornaman Book a free application call: https://dramiehornaman.com/pages/book-a-call FREE DOWNLOADS… What Are the Optimal Lab Ranges? What Steps Can I Take? Don't know where to start...don't know which labs are useful? And what to do when you get your results? “How To” Guide For Supplements Here's your Fixxr® supplement timeline and guide. RATE, REVIEW AND FOLLOW ON APPLE PODCASTS Show your love for Amie and The Thyroid Fixer Podcast! If you're enjoying our journey together, I'd be thrilled if you could take a moment to rate and review the show on Apple Podcasts. Your support helps me reach and help more people just like you, guiding them towards their optimal selves! Just click HERE, scroll all the way down, give us those 5 stars, and share what you enjoy about my episodes in a review. Haven't subscribed yet? Make sure to follow The Thyroid Fixer Podcast to catch all the new episodes that come out every week. Follow HERE and never miss out on a moment of the journey! CONNECT WITH ME ON SOCIAL MEDIA: Join my exclusive Facebook Group, Dr. Amie…The Thyroid Fixer®...Love Your Mirror, for a Community of HOPE and Support in your thyroid journey. https://www.facebook.com/groups/dramie/ Like me on Facebook: Amie Hornaman Nutrition and Functional Medicine Subscribe on Youtube: Dr. Amie Hornaman Follow me on Instagram: @dramiehornaman

This episode is sponsored by CurvaFix®, Inc, the makers of the CurvaFix® IM Implant – Delivering strong, minimally invasive fixation for curved anatomy and poor bone. In this podcast, Brett Crist, MD moderates a conversation about the treatment of elderly patients' who sustain immobility injuries of the pelvis and acetabulum with Julie Switzer, MD and Robert Wetzel, MD. During their conversation they dive into the clinical and economic impact of the current standard of care, how their patient care has evolved over time, patient outcomes, and more! To learn more about the CurvaFix system, please visit our website: CurvaFix

In Episode 36 of "Talk to Me About A&E," Dan is joined by Colleen Palmer, Risk Manager for Beazley, and Lou Gale, GC for the architectural firm SCB, on the Standard of Care.  In Part I of this two-part series we begin the first question asked when a design professional is accused of negligence: What was the applicable standard of care - and was it met?   This discussion will include an overview of what every design professional should know when it comes to the standard of care, as well as how best to educate their clients and manage expectations through effective communication and documentation practices.  

The documentary I want to share with you today is called "A New Standard of Care" by Megan Smith, and it's talking about holistic approaches to healing the body from cancer.About the Host:Melissa is an Integrative Health Practitioner and Master Practitioner in NLP and Timeline Therapy and a Board Designated Hypnotherapy Teacher Trainer, helping people get to the root cause of their health issues and then get lasting results. Melissa neither diagnoses nor cures but helps bring your body back into balance by helping discover your “toxic load” and then removing the toxins. Melissa offers functional medicine lab testing that helps you “see inside” to know exactly what is going on, and then provides a personalized wellness protocol using natural herbs and supplements. Melissa's business is 100% virtual – the lab tests are mailed directly to your home and she specializes in holding your hand and guiding the way to healing so that you don't have to figure it all out on your own.Melissa is the winner of the 2021 & 2022 Quality Care Award by Business From The Heart and is also the recipient of the Alignable “Local Business Person of the Year “Award 2022 for Whistler.Melissa has been featured at a number of Health & Wellness Summits, such as the Health, Wealth & Wisdom Summit, The Power To Profit Summit, The Feel Fan-freaking-tas-tic Summit, the Aim Higher Summit and many more! She has also guested on over 60 different podcasts teaching people about the importance of prioritizing our health and how to get started. Linktree: https://linktr.ee/yourguidedhealthjourney Thanks for listening!If you know somebody who would benefit from this message, or would be an awesome addition to our community, please share it using the social media buttons on this page.Do you have some feedback or questions about this episode? Leave a note in the comment section below! Subscribe to the podcast!If you would like to get automatic updates of new podcast episodes, you can subscribe on the podcast app on your mobile device.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes.  Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?  Guest Author: John Swegle, PharmD, BCPS, BCACP  Music by Good Talk

In this episode of The Standard of Care Podcast, Samantha Johnson and Nick Adams recount their journey from attending conferences to becoming conference speakers on critical medical-legal topics in EMS. They reflect on how these pivotal experiences shaped their current work. The episode dives into highlights from recent EMS conferences, such as South Carolina EMS, Metro Atlanta EMS, and FAST24, where they engaged with street-level medics and addressed critical topics in the ever-evolving landscape of EMS law. Whether you're a seasoned provider or just starting, this episode offers valuable takeaways on the value of EMS conferences, the evolution of the Standard of Care Podcast, and the importance of staying informed and involved in industry developments. Links:National Association of EMS Physicianshttps://naemsp.org/2025 Annual MeetingJanuary 6-11, 2025https://naemsp.org/annual-meeting/ South Carolina EMS Associationhttps://scemsa.org/2025 SCEMSA SymposiumMarch 5-7, 2025https://scemsa.org/ems-symposium Metro Atlanta EMS Conference2025 Metro Atlanta EMS Conference January 30-31, 2025https://www.maemsc.org/ Prisma Health Swamp Rabbit Prehospital Medicine Conference2025 Swamp Rabbit Conference June 17-19, 2025https://www.facebook.com/ghsemsconference/ FAST25(FlightBridgeED Air and Surface Transport Symposium 2025)Lexington, KY | May 19-21, 2025https://fbefast.com FTFC/Gathering of Eagles2025 FTFC/Gathering of Eagles June 9-13, 2025https://firsttherefirstcare.com/ 

Returning guest, Grace's dad Scott Schara chats with Crash Connell. Grace's dad walks through how Standards of Care were designed to kill us and the only solution. He also gives us an update on the lawsuit surrounding Grace's wrongful death. Links: https://ouramazinggrace.net https://rumble.com/c/c-2054162   Stand Up For The Truth's Rumble Page: https://rumble.com/user/CTRNOnline Donate to our Truth mission: https://standupforthetruth.com/donate/

Returning guest, Grace's dad Scott Schara chats with Crash Connell. Grace's dad walks through how Standards of Care were designed to kill us and the only solution. He also gives us an update on the lawsuit surrounding Grace's wrongful death. Links: https://ouramazinggrace.net https://rumble.com/c/c-2054162   Stand Up For The Truth's Rumble Page: https://rumble.com/user/CTRNOnline Donate to our Truth mission: https://www.standupforthetruth.com/donate/

Coro Health's innovative therapeutic music services are revolutionizing care for individuals with dementia, Alzheimer's, and other conditions. David Schofman, Co-Founder and CEO of Coro Health, describes their groundbreaking Music Prescription Builder and compelling evidence from clinical trials showing significant reductions in agitation, depression, medication, and caregiver burden. Learn how digital therapeutics backed by research and world-class neuroscience can elevate the standard of care and improve health outcomes across the continuum of care. Links and notes related to this episode can be found at https://mpetersonmusic.com/podcast/episode187 Connect with us: Newsletter: https://mpetersonmusic.com/subscribe Facebook: https://www.facebook.com/EnhanceLifeMusic/ Instagram: https://www.instagram.com/enhancelifemusic/ LinkedIn: https://www.linkedin.com/in/mpetersonpiano/ Twitter: https://twitter.com/musicenhances Sponsorship information: https://mpetersonmusic.com/podcast/sponsor Leave us a review on Podchaser.com! https://www.podchaser.com/podcasts/enhance-life-with-music-909096 In-episode promo:  Sheet Music Direct https://www.sheetmusicdirect.com The Business Side of Music podcast https://www.businesssideofmusic.com   

A group of doctors has declared that it's time to protect children. Janet Parshall tells you more in her commentary for this week.See omnystudio.com/listener for privacy information.

This episode is brought to you by Cozy Earth, Maui Nui, and Lumebox. We've heard about Dr. Thomas Seyfried's groundbreaking research and approach to cancer as a disease of metabolic dysfunction. Today's guest was inspired by Dr. Seyfried's metabolic approach and conducted his own research on brain cancer cells using ketone-based metabolic therapy and hyperbaric oxygen. His findings were mind-blowing! Today on The Dhru Purohit Podcast, Dhru sits down with Dr. Dominic D'Agostino to discuss his extensive research on brain cancer cells placed in ketosis and under the pressure of hyperbaric oxygen. Dr. D'Agostino shares why his findings provide further insight into the idea that cancer cell growth can be metabolically managed. He also discusses how exercise and a low-carbohydrate diet can be used as metabolic therapies to reduce cancer risk. Dr. D'Agostino shares the critical tests we should focus on to assess our metabolic health and the essential supplements that can support ketosis.  Dr. Dominic D'Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology, where he develops and tests metabolic therapies, including alternative energy substrates and ketogenic agents for neurological disorders, cancer, and wound healing. While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving cancer cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.   In this episode, Dhru and Dr. D'Agostino dive into (audio version / Apple Subscriber version): The most innovative approaches to cancer (00:00:11 / 00:00:11)  The metabolic approach to cancer (1:30/1:30) Using the hyperbaric approach in cancer patients (13:00/ 9:03) The results of Dr. A'gostino's studies on mice (17:00 / 13:50) How this research translates to patients (22:00 / 18:05) Why a ketogenic diet can be therapeutic (37:00 / 32:04) The role of exercise in cancer prevention (53:00 / 46:35) What lifestyle factors should we be doubling down on for prevention (55:00 / 50:14) Dr. D'Agostino's thoughts on a low carbohydrate diet (1:01:00 / 56:30) The therapeutic benefits of ketosis (1:11:00 / 1:06:40) Supplements that can support ketosis (1:19:00 / 1:12:43) How to measure for ketosis (1:24:00 / 1:18:30) Checking the status of your metabolic health (1:26:00 / 1:21:30) Where to find community (1:34:00 / 1:28:16) Also mentioned in this episode: Keto Start Donate to the University of Florida (Metabolic Therapy and Cancer Research #250244) Levels  To learn more about Dr. D'Agostino, follow him on Instagram, Twitter, or his website.  Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code DHRUP. Right now, Maui Nui Venison is offering my community 20% off your first purchase. Just go to mauinuivenison.com/DHRU or enter the code D-H-R-U at check out to get 20% off and up your high-quality protein today. Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 40% off! Go to thelumebox.com/dhru and get your Red Light device.